Evidence map›Paper›PMID 28474310›Full record

ArticleThe AAPS journal2017

Minipig and Human Metabolism of Aldehyde Oxidase Substrates: In Vitro-In Vivo Comparisons.

David J Wilkinson, Rosalind L Southall, Mingguang Li, Lisa M Wright, Lindsay J Corfield, Thomas A Heeley, Benjamin Bratby, Ranbir Mannu, Sarah L Johnson, Victoria Shaw and 4 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Enzyme Kinetics, Pharmacokinetics, and Inhibition of Aldehyde Oxidase.Methods in molecular biology (Clifton, N.J.) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

David J WilkinsonDepartment of Metabolism, Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire, HG3 1PY, UK. david.wilkinson@covance.com.
Rosalind L SouthallDepartment of Metabolism, Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire, HG3 1PY, UK.
Mingguang LiDepartment of Drug Metabolism, Covance Laboratories Inc., Madison, Wisconsin, USA.
Lisa M WrightDepartment of Metabolism, Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire, HG3 1PY, UK.
Lindsay J CorfieldDepartment of Metabolism, Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire, HG3 1PY, UK.
Thomas A HeeleyDepartment of Metabolism, Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire, HG3 1PY, UK.
Benjamin BratbyDepartment of Bioanalysis, Covance Laboratories Ltd., Harrogate, UK.
Ranbir MannuDepartment of Bioanalysis, Covance Laboratories Ltd., Harrogate, UK.
Sarah L JohnsonDepartment of Metabolism, Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire, HG3 1PY, UK.
Victoria ShawDepartment of Metabolism, Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire, HG3 1PY, UK.
Holly L FriettDepartment of Metabolism, Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire, HG3 1PY, UK.
Louise A BlakeburnDepartment of Metabolism, Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire, HG3 1PY, UK.
John S KendrickDepartment of Metabolism, Covance Laboratories Ltd., Otley Road, Harrogate, North Yorkshire, HG3 1PY, UK.
Michael B OttenederPharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Covance (United Kingdom) · GBCovance (United States) · USRoche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The importance of aldehyde oxidase (AOX) is becoming increasingly recognized in the prediction of human pharmacokinetic parameters from animal data. The objectives of these studies were to ascertain whether an in vitro-in vivo correlation existed in the clearance and metabolic pathways of AOX substrates and to establish whether the minipig represented an appropriate non-rodent model for man in the pre-clinical development of drugs metabolized by AOX. Using the AOX substrates carbazeran, 6-deoxypenciclovir and zaleplon, clearance was estimated from in vitro depletion experiments with minipig and human liver cytosol and microsomes and scaled before comparison with data generated in parallel in vivo studies in minipigs. In vitro and in vivo metabolic pathways were characterized by LC-MS/MS. Scaling of in vitro metabolism data to predict in vivo clearance underestimated in vivo values, although the rank order of clearance for the three compounds was preserved. Prediction of human in vivo clearance from scaled minipig in vivo data produced results which correlated well with published clinical values. Overall, this study is the first to compare minipig in vitro metabolism data with in vivo pharmacokinetic data for compounds metabolized by AOX and provides a scientific rationale for the selection of this species as a model for humans in the development of drugs which are substrates of AOX.

Indexed as

Aldehyde OxidaseAnimalsFemaleHumansMaleMicrosomes, LiverSubstrate SpecificitySwineSwine, MiniatureAldehyde Oxidasealdehyde oxidaseanimal modelsin vitro–in vivo predictionminipig

Identifiers

PMID28474310
OpenAlexW2610919671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.